From Yahoo Finance: 2025-04-26 10:15:00

President Donald Trump has paused plans for aggressive tariffs on imported goods for 90 days. Companies like Johnson & Johnson and Novartis are looking to avoid these tariffs by increasing U.S. manufacturing. Johnson & Johnson plans to spend over $55 billion in the U.S. in the next four years.

Despite potential tariff impacts, Johnson & Johnson remains adaptable and successful. With a long history of overcoming challenges, an AAA credit rating, and consistent financial results, investors should consider buying shares. The company has increased payouts for 63 consecutive years, making it a reliable income option.

Novartis is also investing in U.S. manufacturing to avoid tariffs, planning to spend $23 billion to locally manufacture all medicines sold in the U.S. Despite some upcoming patent losses, the company expects 5% revenue growth through 2029. Novartis has increased payouts for 28 consecutive years, making it an attractive dividend stock.

Investors seeking reliable income should consider both Johnson & Johnson and Novartis, despite potential tariff impacts. The companies’ long histories of overcoming challenges, consistent financial performance, and dividend streaks make them solid investment options. Novartis is well-positioned to mitigate the impact of tariffs, while Johnson & Johnson continues to adapt and succeed.

Read more: These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?